Sign up USA
Proactive Investors - Run By Investors For Investors

Soligenix shares skyrocket on RiVax development program news

Ricin is an extremely dangerous poison, which has been used as a weapon and by terrorists.
Soligenix shares skyrocket on RiVax development program news
Ricin has been used as a biological weapon

Soligenix Inc (NASDAQ:SNGX) shares surged over 52% in New York as it posted positive data on its ricin toxin vaccine called RiVax.

Ricin is an extremely dangerous poison, which has been used as a  weapon and by terrorists.

It  can be inhaled, injected, ingested, or absorbed through eyes or damaged skin.

A vaccine against it is hoped to deter its use as a biological weapon.

The firm has shown RiVax has enhanced thermostability and 100% protection in pre-clinical ricin aerosol challenge models and will be showcasing results from the candidate's development program at a conference in Bethesda, Maryland  from April 24  to 26.

It is hoped the findings will aid approval of RiVax by the US Food and Drug Administration (FDA).

Shares added 52.87% to $3.93.

View full SNGX profile View Profile

Soligenix Timeline

Related Articles

picture of cannabis plants
March 23 2018
Control of the supply chain offers operational advantages and financial benefits.
Vial of pills
May 17 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
researcher filling a vial
April 23 2018
2018 is shaping up to be a crucial year for the company's drug pipeline

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use